Investorideas.com – big ideas for global investors Search www.investorideas.com
   Member Access       Sign-up       Newsfeeds        Companies        Stock Directories       Research       Video       Funding   




Category: Investment, Biotech, Pharma

Biotech News Alert: MANAGEMENT OF SUNSHINE BIOPHARMA (OTCQB: SBFM) ALARMED BY THE RECENT WORLD HEALTH ORGANIZATION REPORT THAT CANCER IS ON THE RISE

Ideas get bigger when you share them...

Visit this company: Sunshine Biopharma Inc.

Montreal, Quebec, Canada - March 31, 2014 (Investorideas.com Biotech Newswire) Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer has issued a response to the recently released reports by the World Health Organization and the Pancreatic Cancer Action Network.

Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner

"We are very pleased with the progress we have made thus far in our efforts to re-domicile the Company in Canada," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "We are anxious to complete the re-domiciling process as we have attendant growth and financing opportunities that we believe are available to us once we have completed this action. This is important for the Company’s business strategy overall and for our Adva-27a anticancer drug candidate as we advance towards clinical trials for multidrug resistant breast cancer and pancreatic cancer."

According to "World Cancer Report 2014" issued in February by the World Health Organization, cancer is on the rise and has become a leading cause of death worldwide, accounting for 8.2 million deaths in 2012. Lung cancer accounted for 1.59 million deaths and breast cancer represented half a million deaths. The report also says that cancer cases are expected to rise significantly, "It is expected that annual cancer cases will rise from 14 million in 2012 to 22 million within the next two decades."

Additionally the Pancreatic Cancer Action Network released a special report entitled "The Alarming Rise of Pancreatic Cancer Deaths in the United States: Why We Need to Stem the Tide Today". The report noted that "T(t)he alarming findings presented in the report include the fact that by the year 2020, and possibly as early as 2015, pancreatic cancer will move from the fourth leading cause of cancer death to the second leading cause of cancer death in the United States."

"We are alarmed and impassioned by these trends to move vigorously ahead with our clinical development of Adva-27a for aggressive forms of cancer," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "The Company is planning a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant breast cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada)."

Sunshine Biopharma recently reported that it has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multidrug resistant breast cancer. Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information Contact:

Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com

www.sunshinebiopharma.com

Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM has renewed effective December 3,2013 with Investorideas for six months of news publication and general public awareness of the company news and technologies and products in the biopharma markets ( one hundred thousand shares of 144 stock per 3 month period for a total of six months ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.aspBC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Free News Alerts
Email:  

Read more News





TOP

Investor Ideas © 2000 - 2014 InvestorIdeas.com®, ECON

Free Investor Stock Alerts
Sign up here

login | logout | about us | contact | disclaimer / disclosure |
advertise | company profile directory | partners / links |
job search | privacy policy | trade | services | sitemap |